They are chemically amplifying the restriction that already defines their condition.
A quiet crisis is unfolding at the intersection of pharmacology and psychiatric vulnerability, as GLP-1 medications — designed to ease the burden of metabolic disease — are being drawn into the logic of eating disorders, where appetite suppression is not a side effect but a goal. Across the country, clinicians are encountering patients who have obtained semaglutide and similar drugs not to heal, but to deepen a form of self-erasure that was already underway. The same mechanism that offers relief to one person becomes an instrument of harm in another's hands — a reminder that no tool is neutral when the mind wielding it is in crisis. The healthcare system now faces the difficult work of protecting the vulnerable without abandoning those for whom these medicines are genuinely lifesaving.
- People with anorexia and bulimia are actively seeking out GLP-1 drugs to chemically reinforce restriction, turning a metabolic medication into a psychiatric weapon turned inward.
- Telehealth platforms and loosely regulated online prescribers have made it possible to obtain these drugs without disclosing an eating disorder, creating dangerous gaps in the safety net.
- Patients are arriving in clinics with severe malnutrition, cardiac-threatening electrolyte imbalances, and worsening depression and anxiety — complications layered on top of already fragile conditions.
- The overlap between GLP-1 side effects and eating disorder symptoms — nausea, vomiting, abdominal pain — means serious deterioration can go unrecognized and unmonitored for far too long.
- Clinicians and health systems are pushing for mandatory mental health screening before prescribing, but fear that tighter restrictions may simply redirect vulnerable people toward even less regulated sources.
- Medicine is caught in a bind: restrict access and risk harming those with legitimate metabolic need; leave the system unchanged and watch psychiatric illness accelerate under pharmaceutical cover.
Doctors across the country are witnessing a troubling convergence: patients with eating disorders are obtaining GLP-1 medications — drugs like semaglutide developed for diabetes and obesity — and using them not for metabolic health, but to intensify restriction. These medications suppress appetite and slow digestion, effects that are genuinely therapeutic in their intended context. But for someone already trapped in cycles of food avoidance and control, those same effects become a means of going further, faster, into dangerous territory.
The clinical consequences are severe. Physicians describe patients arriving with profound malnutrition, electrolyte imbalances capable of triggering cardiac arrhythmias, and psychiatric symptoms that have worsened in tandem with the drug's appetite-suppressing action. Complicating matters further, GLP-1 side effects — nausea, vomiting, gastrointestinal distress — can mask the very complications they are worsening, leaving serious deterioration undetected in patients who are not seeking regular monitoring.
Access is at the heart of the crisis. Telehealth platforms, compounding pharmacies, and online prescribers have made these medications widely available to people who may not disclose — or may actively conceal — an eating disorder diagnosis. Cheaper, less regulated versions circulate beyond traditional pharmacy channels, reaching people who might otherwise be priced out entirely.
The medical community is calling for systemic reform: mental health screening before prescribing, mandatory psychiatric clearance in some proposals, and stricter follow-up protocols. But these measures remain uneven, and a harder tension persists beneath them. GLP-1 drugs are genuinely valuable for many people managing serious metabolic conditions. Restricting access to protect those with eating disorders risks harming others who depend on these medications. Yet leaving the current system in place means watching a powerful appetite suppressant accelerate the deterioration of people already in psychiatric crisis — a harm that is quiet, incremental, and very difficult to stop.
Across the country, doctors are watching a troubling pattern emerge in their clinics: patients with eating disorders are obtaining GLP-1 medications—drugs designed to help people with diabetes and obesity manage their weight—and using them to deepen their restriction. The medications, which include semaglutide and other glucagon-like peptide-1 agonists, work by suppressing appetite and slowing gastric emptying, effects that make them genuinely useful for their intended purposes. But for someone already locked in a cycle of food avoidance and control, these same mechanisms become a tool for harm.
The medical community's alarm is grounded in hard reality. A person with an eating disorder who takes a GLP-1 drug is not simply losing weight more efficiently. They are chemically amplifying the restriction that already defines their condition. The medication makes it easier to eat less, to ignore hunger signals, to push further into dangerous territory. Doctors describe patients arriving at appointments with severe malnutrition, electrolyte imbalances that can trigger cardiac arrhythmias, and psychiatric symptoms that have worsened alongside the drug's appetite-suppressing effects.
What makes this crisis particularly difficult to contain is access. GLP-1 medications have become widely available through telehealth platforms, compounding pharmacies, and online prescribers who may not have full visibility into a patient's psychiatric history. Someone with bulimia or anorexia nervosa can obtain these drugs without necessarily disclosing their eating disorder, or they may find prescribers willing to overlook red flags in pursuit of a straightforward weight-loss transaction. The medications are expensive when purchased through traditional channels, but cheaper versions circulate through less regulated markets, making them accessible to people who might otherwise be priced out.
The risks extend beyond the immediate effects of appetite suppression. GLP-1 drugs can cause nausea, vomiting, and gastrointestinal distress—symptoms that overlap with and can mask the complications of eating disorders themselves. A patient experiencing severe abdominal pain might attribute it to the medication rather than to the underlying malnutrition or organ stress. Electrolyte depletion, which can be life-threatening, may go undetected because the person is not seeking regular medical monitoring. The psychiatric dimension is equally concerning: these medications can worsen anxiety and depression in vulnerable individuals, potentially deepening the psychological grip of the eating disorder.
Medical professionals are calling for systemic change. They argue that prescribing protocols need to include mental health screening before GLP-1 medications are dispensed, particularly through telehealth channels where in-person assessment is impossible. Some advocate for mandatory psychiatric clearance, though others worry this could simply push vulnerable people toward even less regulated sources. Healthcare systems are beginning to implement stricter monitoring—requiring baseline labs, follow-up appointments, and explicit screening for eating disorder symptoms—but these measures remain inconsistent across providers and regions.
The core problem is one of competing harms. GLP-1 medications genuinely help many people manage serious metabolic conditions. Restricting access to protect those with eating disorders could harm those who need these drugs for legitimate medical reasons. Yet leaving the current system unchanged means watching people with psychiatric illness use a powerful appetite suppressant to accelerate their own deterioration. Doctors are caught between these poles, trying to prescribe responsibly while knowing that somewhere, someone with an eating disorder is finding another way to obtain the drug they believe will finally let them disappear.
Notable Quotes
Medical professionals are calling for systemic change, including mental health screening before GLP-1 medications are dispensed— Healthcare providers and doctors
The Hearth Conversation Another angle on the story
Why are people with eating disorders specifically drawn to these medications? They're not marketed for that purpose.
Because they do exactly what the eating disorder wants them to do. They make hunger go away. They make it easier to eat less. For someone already fighting their own body, that's an irresistible tool.
But surely doctors can see the warning signs when someone with an eating disorder tries to get a prescription?
Not always. Telehealth makes it easier to hide. You fill out a form, you talk to a doctor for fifteen minutes who's never seen you before, and you don't have to mention the eating disorder at all. Or you find a prescriber who doesn't ask the right questions.
What happens to someone's body when they combine an eating disorder with a GLP-1 drug?
It accelerates everything bad. The malnutrition gets worse faster. Electrolytes drop dangerously. The heart can start misfiring. And because the medication is suppressing appetite, the person doesn't feel the usual warning signs their body would normally send.
Is there a way to prescribe these drugs safely to people with eating disorders?
Theoretically, yes—with intensive psychiatric monitoring, regular labs, close follow-up. But that's expensive and time-consuming. Most of the system isn't set up for it. It's easier to just not prescribe to them at all, but that requires catching them first.
What do doctors wish had happened differently?
They wish the drugs had never become so easy to get without real oversight. They wish there were mandatory mental health screening. They wish people understood that appetite suppression isn't the same as health.